loading
Esperion Therapeutics Inc stock is traded at $2.17, with a volume of 4.86M. It is up +1.88% in the last 24 hours and up +77.87% over the past month. Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
See More
Previous Close:
$2.13
Open:
$2.14
24h Volume:
4.86M
Relative Volume:
1.08
Market Cap:
$437.52M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-1.0236
EPS:
-2.12
Net Cash Flow:
$-135.49M
1W Performance:
+5.85%
1M Performance:
+77.87%
6M Performance:
+19.23%
1Y Performance:
+26.90%
1-Day Range:
Value
$2.13
$2.20
1-Week Range:
Value
$2.00
$2.20
52-Week Range:
Value
$0.6925
$3.94

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Name
Name
Esperion Therapeutics Inc
Name
Phone
734-887-3903
Name
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Name
Employee
304
Name
Twitter
@esperioninc
Name
Next Earnings Date
2025-03-04
Name
Latest SEC Filings
Name
ESPR's Discussions on Twitter

Compare ESPR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
ESPR
Esperion Therapeutics Inc
2.17 423.41M 116.33M -209.25M -135.49M -2.12
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
156.62 67.51B 9.39B 2.62B 2.22B 5.81
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.52 47.88B 29.96B 957.25M 4.77B 0.304
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.82 43.42B 14.26B 1.98B 2.47B 0.4347
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
18.46 20.72B 16.70B -157.13M 1.19B -0.155
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
312.23 14.21B 2.99B 1.21B 1.13B 25.06

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-18-24 Initiated Goldman Neutral
Dec-17-24 Initiated Cantor Fitzgerald Overweight
Jun-20-24 Downgrade BofA Securities Neutral → Underperform
Jan-03-24 Downgrade BofA Securities Buy → Neutral
Nov-20-23 Resumed JP Morgan Neutral
Aug-01-23 Upgrade Northland Capital Under Perform → Market Perform
Jun-15-23 Upgrade BofA Securities Underperform → Buy
Mar-16-23 Downgrade BofA Securities Neutral → Underperform
Mar-16-23 Downgrade Northland Capital Market Perform → Under Perform
Mar-07-23 Upgrade Credit Suisse Underperform → Neutral
Feb-27-23 Resumed BofA Securities Neutral
Feb-24-23 Upgrade Jefferies Hold → Buy
Feb-03-23 Upgrade Morgan Stanley Underweight → Equal-Weight
Aug-03-22 Downgrade Credit Suisse Neutral → Underperform
May-05-22 Upgrade JP Morgan Underweight → Neutral
Mar-10-22 Initiated H.C. Wainwright Buy
Oct-19-21 Downgrade Credit Suisse Outperform → Neutral
Oct-14-21 Downgrade Morgan Stanley Equal-Weight → Underweight
May-05-21 Downgrade Stifel Buy → Hold
Apr-26-21 Resumed Credit Suisse Outperform
Mar-11-21 Initiated Morgan Stanley Equal-Weight
Feb-12-21 Downgrade Jefferies Buy → Hold
Feb-09-21 Downgrade Goldman Neutral → Sell
Jan-15-21 Downgrade BofA Securities Buy → Neutral
Nov-10-20 Upgrade Credit Suisse Neutral → Outperform
Sep-29-20 Resumed JP Morgan Underweight
Aug-11-20 Downgrade Credit Suisse Outperform → Neutral
Apr-01-20 Resumed BofA/Merrill Buy
Mar-17-20 Upgrade Citigroup Neutral → Buy
Feb-24-20 Downgrade Northland Capital Outperform → Market Perform
Feb-14-20 Downgrade Citigroup Buy → Neutral
Sep-16-19 Upgrade Goldman Sell → Neutral
May-29-19 Downgrade Goldman Neutral → Sell
May-06-19 Upgrade BofA/Merrill Underperform → Neutral
Apr-26-19 Upgrade Goldman Sell → Neutral
Mar-13-19 Upgrade JP Morgan Underweight → Neutral
Jan-07-19 Reiterated Needham Strong Buy
Dec-13-18 Initiated Goldman Sell
Oct-29-18 Upgrade Northland Capital Market Perform → Outperform
Oct-16-18 Initiated BTIG Research Buy
Aug-17-18 Upgrade Citigroup Neutral → Buy
Jul-11-18 Downgrade Northland Capital Outperform → Market Perform
May-03-18 Downgrade JP Morgan Neutral → Underweight
May-02-18 Downgrade BofA/Merrill Buy → Underperform
View All

Esperion Therapeutics Inc Stock (ESPR) Latest News

pulisher
Aug 20, 2025

Esperion rises after revenue beat, Q1 profitability expectation - MSN

Aug 20, 2025
pulisher
Aug 19, 2025

Three Analyst Favorites with Potential for Further Gains: SkyWater Technology, Emergent BioSolutions, and More - AInvest

Aug 19, 2025
pulisher
Aug 18, 2025

Detecting support and resistance levels for Esperion Therapeutics Inc.Stock Surge & Safe Entry Momentum Tips - Newser

Aug 18, 2025
pulisher
Aug 18, 2025

Chart based analysis of Esperion Therapeutics Inc. trendsWeekly Market Report & AI Forecasted Entry/Exit Points - Newser

Aug 18, 2025
pulisher
Aug 18, 2025

Is Esperion Therapeutics Inc. still worth holding after the dip2025 Short Interest & Community Consensus Picks - Newser

Aug 18, 2025
pulisher
Aug 18, 2025

Esperion Therapeutics soars amid vague takeover speculation - MSN

Aug 18, 2025
pulisher
Aug 17, 2025

Best data tools to analyze Esperion Therapeutics Inc. stockTrade Risk Report & Risk Controlled Daily Plans - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Esperion Therapeutics Inc. stock outlook for YEARPortfolio Update Report & Stepwise Entry/Exit Trade Alerts - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Is Esperion Therapeutics Inc. a Top Dividend Stock to Watch in 2025Market Movers & AI Based Trade Execution Alerts - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Applying sector rotation models to Esperion Therapeutics Inc.Market Growth Summary & Free Low Drawdown Momentum Trade Ideas - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Esperion Therapeutics (NASDAQ:ESPR) Upgraded at Wall Street Zen - Defense World

Aug 17, 2025
pulisher
Aug 17, 2025

Pattern recognition hints at Esperion Therapeutics Inc. upsideStock Surge & Risk Adjusted Buy/Sell Alerts - Newser

Aug 17, 2025
pulisher
Aug 16, 2025

What MACD signals say about Esperion Therapeutics Inc.July 2025 PostEarnings & Step-by-Step Swing Trade Plans - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Real time scanner hits for Esperion Therapeutics Inc. explainedJuly 2025 Earnings & Smart Money Movement Alerts - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Will Esperion Therapeutics Inc. price bounce be sustainableCEO Change & Daily Market Momentum Tracking - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

What the charts say about Esperion Therapeutics Inc. today2025 Price Targets & Long Hold Capital Preservation Tips - Newser

Aug 16, 2025
pulisher
Aug 15, 2025

Is Esperion Therapeutics Inc. stock poised for growth2025 EndofYear Setup & Stock Portfolio Risk Control - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Backtesting results for Esperion Therapeutics Inc. trading strategiesWeekly Gains Summary & Breakout Confirmation Trade Signals - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Assessing Madrigal Pharmaceuticals' Long-Term Market Potential in the LDL-C Lowering Therapy Sector Amid Competitive Dynamics - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Is a relief rally coming for Esperion Therapeutics Inc. holdersDollar Strength & Free High Accuracy Swing Entry Alerts - Newser

Aug 15, 2025
pulisher
Aug 14, 2025

Signal strength of Esperion Therapeutics Inc. stock in tech scannersJuly 2025 Update & Short-Term Trading Opportunity Alerts - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

Can Esperion Therapeutics Inc. Regain Momentum After BreakdownJuly 2025 Rallies & Safe Entry Trade Reports - beatles.ru

Aug 14, 2025
pulisher
Aug 13, 2025

What earnings revisions data tells us about Esperion Therapeutics Inc.Quarterly Profit Review & Real-Time Buy Signal Notifications - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

Wall Street Zen Upgrades Esperion Therapeutics (NASDAQ:ESPR) to "Hold" - MarketBeat

Aug 13, 2025
pulisher
Aug 12, 2025

Esperion Delays Q2 2025 Financial Report Filing - MSN

Aug 12, 2025
pulisher
Aug 12, 2025

Competitive Positioning of Esperion Therapeutics Inc.: Is It Leading or LaggingFree Intraday Trend Analysis for Fast Gains - Newser

Aug 12, 2025
pulisher
Aug 10, 2025

Published on: 2025-08-10 18:32:11 - beatles.ru

Aug 10, 2025
pulisher
Aug 10, 2025

FY2025 EPS Estimates for ESPR Boosted by Cantor Fitzgerald - Defense World

Aug 10, 2025
pulisher
Aug 09, 2025

Esperion Therapeutics Inc. At Decision Level — Rebound or ResistanceExpert Verified Stock Trade Ideas Backed by Data - beatles.ru

Aug 09, 2025
pulisher
Aug 09, 2025

ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises - MSN

Aug 09, 2025
pulisher
Aug 09, 2025

Esperion Therapeutics (NASDAQ:ESPR) Upgraded to Hold at Wall Street Zen - Defense World

Aug 09, 2025
pulisher
Aug 09, 2025

HC Wainwright Issues Positive Outlook for ESPR Earnings - Defense World

Aug 09, 2025
pulisher
Aug 08, 2025

Published on: 2025-08-08 10:01:24 - beatles.ru

Aug 08, 2025
pulisher
Aug 07, 2025

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) for New Employees - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Aug 07, 2025
pulisher
Aug 07, 2025

Esperion Grants 73,500 RSUs with 4-Year Vesting Schedule to Attract Top Talent - Stock Titan

Aug 07, 2025
pulisher
Aug 06, 2025

Esperion Therapeutics’ Earnings Call Highlights Growth - The Globe and Mail

Aug 06, 2025
pulisher
Aug 06, 2025

Esperion (ESPR) Q2 Revenue Jumps 12% - AOL.com

Aug 06, 2025
pulisher
Aug 06, 2025

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates - MSN

Aug 06, 2025
pulisher
Aug 06, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 06, 2025
pulisher
Aug 06, 2025

Esperion expects sustainable profitability in Q1 2026 as double-digit growth continues - MSN

Aug 06, 2025
pulisher
Aug 06, 2025

Esperion Therapeutics: Q2 Earnings Snapshot - New Haven Register

Aug 06, 2025
pulisher
Aug 06, 2025

What institutional flow reveals about Esperion Therapeutics Inc.Long-Term Stock Growth Forecast Insights - Newser

Aug 06, 2025
pulisher
Aug 06, 2025

Esperion Therapeutics Inc (ESPR) Q2 2025 Earnings Call Highlights: Strong US Net Product ... By GuruFocus - Investing.com Canada

Aug 06, 2025
pulisher
Aug 06, 2025

Esperion Therapeutics Reports Strong Q2 2025 Growth - TipRanks

Aug 06, 2025

Esperion Therapeutics Inc Stock (ESPR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Esperion Therapeutics Inc Stock (ESPR) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Halladay Benjamin
Chief Financial Officer
Jul 17 '25
Sale
1.11
11
12
474,462
$29.75
price up icon 2.37%
$17.91
price up icon 2.40%
drug_manufacturers_specialty_generic RDY
$14.51
price up icon 0.62%
$10.65
price down icon 0.37%
$135.43
price up icon 0.11%
$312.23
price up icon 0.51%
Cap:     |  Volume (24h):